Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

Item

http://www.wikidata.org/entity/Q36402874

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Soluble KIT correlates with cl ...... cancer treated with sunitinib

@ast

Soluble KIT correlates with cl ...... cancer treated with sunitinib

@en

type

Item

label

Soluble KIT correlates with cl ...... cancer treated with sunitinib

@ast

Soluble KIT correlates with cl ...... cancer treated with sunitinib

@en

prefLabel

Soluble KIT correlates with cl ...... cancer treated with sunitinib

@ast

Soluble KIT correlates with cl ...... cancer treated with sunitinib

@en

P1476

Soluble KIT correlates with cl ...... cancer treated with sunitinib

@en

P2093

Charles S Harmon

http://www.w3.org/2001/XMLSchema#string

Kenneth A Kern

http://www.w3.org/2001/XMLSchema#string

Kiana Keyvanjah

http://www.w3.org/2001/XMLSchema#string

Samuel E DePrimo

http://www.w3.org/2001/XMLSchema#string

William Carley

http://www.w3.org/2001/XMLSchema#string

Xin Huang

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

P2888

1479-5876-10-165

P304

165

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-10-165

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230684533

http://www.w3.org/2001/XMLSchema#string

P6179

1033075198

http://www.w3.org/2001/XMLSchema#string

P698

22897944

http://www.w3.org/2001/XMLSchema#string

P932

3499375

http://www.w3.org/2001/XMLSchema#string